Article Text

Download PDFPDF
222 Acceptance, feasibility and tolerance of dose dense weekly paclitaxel therapy for epithelial ovarian cancer cases – a pilot study from northern India
  1. Aparna Jha and
  2. Shuchi Agrawal
  1. King George’s Medical University, Lucknow, India


Introduction/Background Every year, 240,000 women are diagnosed with ovarian cancer with a five-year survival rate of less than 45%. Majority of ovarian cancer (85% to 90%) is epithelial in origin. Therefore, both surgery and chemotherapy are required for comprehensive disease treatment.Standard chemotherapy includes three weekly carboplatin and paclitaxel. Dose dense weekly paclitaxel regimen is a new approach to this chemotherapy showing higher efficacy and lesser side effects in some trials.

Methodology It was a prospective pilot study conducted over a period of 18 months aimed to analyze acceptance, tolerance and compliance of dose dense weekly paclitaxel therapy in epithelial carcinoma and to compare the side effects and toxicities with 3 weekly paclitaxel regimen.

Institutional ethical clearance was obtained from IEC of KGMU and written informed consent was taken from all recruited patients. Total 38 patients of EOC were included in which 18 cases received weekly dose dense paclitaxel therapy and 20 controls received three weekly paclitaxel therapy. After every chemotherapy course, evaluation was done for side effects and they were recorded grade wise from G0-G6 according to CTCAEv5.0 (Common Terminology Criteria for Adverse Events).Comparison and analysis of incidence and severity of side effects was done using chi-square test and student t test using SPSS software (version 26).

Results The Grade 2 and above severity of side effects (arthralgia, myalgia, diarrhoea and nausea - vomiting) were significantly (p<0.0001) less common with weekly dose dense paclitaxel therapy. Mean grade of severity of all above side effects were also significantly (p<0.0001) lower in weekly regimen.

Conclusion The dose dense weekly paclitaxel regimen was well accepted, feasible and tolerated cases of epithelial ovarian carcinoma.

Disclosures There are no disclosures or conflict of interest in this presentation.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.